Bruce Power announced that it, in collaboration with Isogen, Saugeen Ojibway Nation and ITM Isotope Technologies Munich have taken another important step in increasing medical isotope supplies for treatment of cancer patients around the world.
The group is in the first phase of its steps to increase the amount lutetium-177 that is produced in the Bruce Unit 7 reactor core.
It is used in precision oncology for targeted therapy of a growing number of cancers.
Bruce Power and its partners were the first to produce the short-lived medical isotope back in 2022.
The collaboration with Saugeen Ojibway Nation is to market the new isotope supply in an equity partnership while creating new economic opportunities for the territory.
